Ionis Pharmaceuticals, Inc. (IONS) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)

Company Overview - Ionis has achieved significant progress recently, highlighted by the FDA approval of DAWNZERA, the first RNA-targeted medicine for the prophylactic treatment of hereditary angioedema [1] - The company is currently focused on launching its products operationally, with early indications showing positive results [2] Key Initiatives - Ionis shared top-line data from the Phase III study of olezarsen for severe hypertriglyceridemia, which showed remarkable outcomes for a disease that requires more effective treatments [2] - The company is preparing for a supplemental NDA to advance the olezarsen drug following the successful study results [3]